about
Patterns of Glaucoma Medication Adherence over Four Years of Follow-UpPrimary Open-Angle Glaucoma Suspect Preferred Practice Pattern(®) Guidelines.Primary Angle Closure Preferred Practice Pattern(®) Guidelines.Primary Open-Angle Glaucoma Preferred Practice Pattern(®) Guidelines.Geographic and climatic factors associated with exfoliation syndrome.Filtering data from the collaborative initial glaucoma treatment study for improved identification of glaucoma progression.Use of health care claims data to study patients with ophthalmologic conditionsMechanisms of action and efficacy of argon laser trabeculoplasty and selective laser trabeculoplasty.The potential association between postmenopausal hormone use and primary open-angle glaucoma.Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year periodCost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma.Serious adverse events after cataract surgery.Risk factors associated with developing branch retinal vein occlusion among enrollees in a United States managed care plan.Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users.Diffusion of technologies for the care of older adults with exudative age-related macular degeneration.Racial disparities in the use of ancillary testing to evaluate individuals with open-angle glaucoma.Adverse events after pars plana vitrectomy among medicare beneficiaries.Effect of gestational age and birth weight on the risk of strabismus among premature infants.Racial differences in age-related macular degeneration rates in the United States: a longitudinal analysis of a managed care networkBupropion use and risk of open-angle glaucoma among enrollees in a large U.S. managed care network.Quality of life with macular degeneration: perceptions of patients, clinicians, and community members.Subsequent Receipt of Interventions for Glaucoma Among a Nationwide Sample of Patients Who Underwent Laser Peripheral IridotomyDisparities between ophthalmologists and their patients in estimating quality of life.Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease.Using filtered forecasting techniques to determine personalized monitoring schedules for patients with open-angle glaucoma.Trends in use of ancillary glaucoma tests for patients with open-angle glaucoma from 2001 to 2009Impact of the introduction of generic latanoprost on glaucoma medication adherence.Rates of glaucoma medication utilization among older adults with suspected glaucoma, 1992 to 2002Hospitalization after Cataract Surgery in a Nationwide Managed-Care PopulationAssociation of Geroprotective Effects of Metformin and Risk of Open-Angle Glaucoma in Persons With Diabetes Mellitus.Keratoplasty for corneal endothelial disease, 2001-2009.Comparison of Outcomes of Laser Trabeculoplasty Performed by Optometrists vs Ophthalmologists in Oklahoma.Age-related macular degeneration: economic burden and value-based medicine analysis.Longitudinal trends in resource use in an incident cohort of open-angle glaucoma patients: resource use in open-angle glaucomaThe relationship between statin use and open-angle glaucomaGlaucoma associated with Boston type I keratoprosthesisThe Association Between Sociodemographic Factors, Common Systemic Diseases, and Keratoconus: An Analysis of a Nationwide Heath Care Claims Database.Longitudinal rates of postoperative adverse outcomes after glaucoma surgery among medicare beneficiaries 1994 to 2005Predicting development of proliferative diabetic retinopathy
P50
Q27304671-2FA5FA14-3C70-438B-B64A-A8D5489965CFQ30278065-683011E4-D5A8-471F-AA73-6762D6C296E1Q30278068-9E5A07B4-434E-48F5-98DF-F9BD0E8777A3Q30278069-771D2A81-0010-49B3-8644-E895E37E5F9DQ30465036-0CDCA5BF-9A82-44E4-81F8-3874C420B5D9Q30721357-6AE34825-9B79-41B5-81F0-61DAF529B3BEQ30735544-C3BD14B6-4DCA-471D-A9CA-8C7A290894C2Q33273852-C83F0338-CB84-479E-AE75-0EBB5AEBABC1Q33930485-F723EC6D-AF8C-4BFD-A46A-6951F9F21BD9Q33944980-885D28A3-0053-4AD9-A0DD-4B898C138107Q34062494-82243561-9A5B-43FE-87C9-0DD0FD206264Q34158299-F4EEFF5D-CF28-432D-B3CF-37F283CCF1F9Q34208343-076321C7-0E9C-43DE-AD97-722810CB9F47Q34257625-5114BF37-092D-4B48-BF19-1B0C7F303429Q34315879-3C9E64CC-4D04-4841-B4BC-53B3BCA15154Q34503375-0CBC872C-58CC-4C69-B165-F8F4B17CBA23Q34508222-D7EDAE1D-FCD6-454F-9301-74D39F672694Q34796388-70BBDD5B-0C87-445B-A143-209A48CB0FADQ35118986-52915905-64D8-4A2B-8A97-461B7995C8CCQ35127011-A03A5FCD-A2D9-4BB2-906F-10C8DA3488E2Q35391594-85CDDD9D-7D3B-4C0C-8762-07B3905FD7F3Q35590440-CF9E5F63-7522-488F-95A6-C397A8C5C44CQ35620824-B7D4F839-BFD7-41B1-9A81-DDED1D844961Q35760600-2F81CC6B-D6E2-449D-B20A-7F5A68E4F33AQ35830997-E0472839-2590-44C0-80AC-A22CA2E7E2B7Q35831076-6B45717E-832C-4F3E-B79E-3A810A4C2F9AQ35871555-543A7396-9E95-4482-B753-085232DD3592Q35899865-0247BFE0-7EC9-486D-B5B4-7B51A7417AA0Q35915939-4C3A8D59-D56B-46D6-8D0F-EC5A283F4008Q35931205-92033A69-A9D6-4384-BFEC-5F946F65534FQ35956368-ADE511A9-BF98-4E0E-988F-D5801E99969DQ36074521-4DC642B4-B212-496D-AFB2-54DEC03501CDQ36088472-63B857A6-A053-4918-BD49-52EE9F531E31Q36157996-30CC216B-9180-4DF1-9967-E0FBDA21C428Q36173758-A0AD08B3-2C5A-494B-98B4-75214FC54280Q36282796-EE7C12C5-FAEA-40CC-A2F4-026C7B4E64F6Q36515144-09BE6FBF-1A71-4A51-BFA4-7F0FEB8CB394Q36614522-AACBFC0B-88A4-4AB2-B95F-4DA03E96FF6EQ36621663-14701E8D-77D4-4E41-BF2D-A170CACE07B5Q36868163-B58BDD27-E5B9-4EAD-AA4F-378BCE076461
P50
description
Forscher
@de
investigador
@es
onderzoeker
@nl
researcher
@en
ricercatore
@it
研究員
@ja
研究者
@zh
name
J D Stein
@en
J D Stein
@nl
type
label
J D Stein
@en
J D Stein
@nl
prefLabel
J D Stein
@en
J D Stein
@nl
P106
P31
P496
0000-0003-2937-6987